SALT LAKE CITY, April 21, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced its participation as a presenter last week at STM 2015: The 32nd Annual Meeting of the Society for Thermal Medicine, held in Orlando, Florida.
Representing Perseon, Senior Scientist Mark J. Hagmann Ph.D. presented "Principles for Accurate Simulations of Microwave Ablation" during STM's Thermal Modeling and Devices Symposium held on April 15th. Dr. Hagmann demonstrated how Perseon's methods, utilizing MicroThermX® technology, can better predict and optimize cancer treatment options and patient outcomes.
"Mark is a renowned thought leader in energy ablation and his remarks at STM 2015 demonstrate Perseon's ongoing recognition as a leading innovator," said Clint Carnell, CEO of Perseon. "Our participation at STM 2015 illustrates our focus on marketing and education initiatives that advance the understanding of our market leading technology."
Dr. Hagmann received a Ph.D. in Electrical Engineering from the University of Utah on "Numerical Studies of absorption of electromagnetic Energy by Man" (1981), followed by five years (1982-1986) studying microwave hyperthermia as a Senior Staff Fellow at the National Institutes of Health (NIH), and 14 years (1986-2000) as a Professor in Electrical and Computer Engineering at Florida International University. Dr. Hagmann has worked for Perseon since 2000, and he is a member of the American Physical Society, the Institute of Electrical and Electronics Engineers (IEEE), and a Fellow in the Electromagnetics Academy. Mark has 124 publications in refereed technical and scientific journals, and has given 289 presentations at international meetings.
Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 email@example.com